A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

NCT02477709 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
6
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)